IGM Biosciences has been granted a patent for binding molecules that include modified antibodies with a binding moiety that antagonizes a T-cell inhibitory signaling pathway. The antibodies can be IgM, IgA, IgG/IgM, or IgG/IgA antibodies and can form pentamers. The modified J-chain of the antibodies contains the binding moiety, which can bind to cell surface proteins involved in T-cell inhibition. GlobalData’s report on IGM Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on IGM Biosciences, personalized cancer vaccines was a key innovation area identified from patents. IGM Biosciences's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for modified antibodies that antagonize t-cell inhibitory signaling
A recently granted patent (Publication Number: US11639389B2) describes an antibody with potential applications in cancer treatment. The antibody consists of five IgM antibody monomers or five IgG/IgM antibody monomers that form a pentamer. It also includes a modified J-chain, which contains a binding moiety that antagonizes a T-cell inhibitory signaling pathway. The binding moiety is attached to the modified J-chain at either the C- or N-terminus of the binding moiety or between cysteine residues 92 and 101 of the modified J-chain. The modified J-chain binds to a cell surface protein, such as CTLA4, PD-1, TIM3, LAG3, BTLA, VISTA, or TIGIT.
The antibody monomers in the composition have antigen-binding sites that can either antagonize a T-cell inhibitory signaling pathway or agonize a T-cell stimulatory signaling pathway. The antigen-binding sites can bind to various targets, including PD-1, PD-L1, TIM3, LAG3, CD137, OX40, CD40, GITR, CD27, HVEM, EGFR, HER2, HER3, EpCAM, CEACAM, Gp100, MAGE1, PD-L1, NY-ESO-1, Sialyl Lewis X antigen, Tn antigen, CD19, CD20, CD22, CD33, CD38, CD52, and CD70.
The modified J-chain is attached to SEQ ID NO: 1, either directly or indirectly via a peptide linker. The introduction of the binding moiety into the native human J-chain sequence of SEQ ID NO: 1 can be achieved through chemical or chemo-enzymatic derivatization. Additionally, a cleavable or non-cleavable chemical linker can be used to introduce the binding moiety into SEQ ID NO: 1.
The binding moiety of the modified J-chain can take various forms, including antigen-binding fragments of antibodies, antibody-drug conjugates, antibody-like molecules, antigen-binding fragments of antibody-like molecules, ligands, and receptors. Specifically, the binding moiety can be an antigen-binding fragment of an antibody, such as F(ab')2, Fab', Fab, Fv, scFv, or single domain antibody.
The patent also mentions a pharmaceutical composition for the treatment of cancer, which includes an effective amount of the antibody described above and a pharmaceutically acceptable carrier.
Overall, this patent describes an antibody with a modified J-chain that can bind to specific cell surface proteins and has the potential to antagonize or agonize T-cell signaling pathways. The antibody's ability to bind to a wide range of targets makes it a promising candidate for cancer treatment.
To know more about GlobalData’s detailed insights on IGM Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
